Sanofi SA (SAN) - Net Assets

Latest as of December 2025: €71.71 Billion EUR

Based on the latest financial reports, Sanofi SA (SAN) has net assets worth €71.71 Billion EUR as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€126.81 Billion) and total liabilities (€55.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€71.71 Billion
% of Total Assets	56.55%
Annual Growth Rate	12.18%
5-Year Change	3.88%
10-Year Change	24.23%
Growth Volatility	106.28

Sanofi SA - Net Assets Trend (1999–2025)

This chart illustrates how Sanofi SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sanofi SA (1999–2025)

The table below shows the annual net assets of Sanofi SA from 1999 to 2025.

Year	Net Assets	Change
2025-12-31	€71.71 Billion	-7.90%
2024-12-31	€77.86 Billion	+4.71%
2023-12-31	€74.35 Billion	+1.83%
2022-12-31	€73.02 Billion	+5.77%
2021-12-31	€69.03 Billion	+8.94%
2020-12-31	€63.37 Billion	+7.21%
2019-12-31	€59.11 Billion	+0.12%
2018-12-31	€59.03 Billion	+1.37%
2017-12-31	€58.24 Billion	+0.89%
2016-12-31	€57.72 Billion	-0.83%
2015-12-31	€58.21 Billion	+3.45%
2014-12-31	€56.27 Billion	-1.34%
2013-12-31	€57.03 Billion	-0.75%
2012-12-31	€57.47 Billion	+1.94%
2011-12-31	€56.37 Billion	+5.79%
2010-12-31	€53.29 Billion	+9.99%
2009-12-31	€48.45 Billion	+7.49%
2008-12-31	€45.07 Billion	+0.79%
2007-12-31	€44.72 Billion	-2.40%
2006-12-31	€45.82 Billion	-1.07%
2005-12-31	€46.32 Billion	+11.55%
2004-12-31	€41.52 Billion	+555.97%
2003-12-31	€6.33 Billion	+4.49%
2002-12-31	€6.06 Billion	+4.65%
2001-12-31	€5.79 Billion	+33.63%
2000-12-31	€4.33 Billion	+19.97%
1999-12-31	€3.61 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Sanofi SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 6687700000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	€66.88 Billion	93.70%
Common Stock	€2.44 Billion	3.42%
Other Components	€2.06 Billion	2.89%
Total Equity	€71.38 Billion	100.00%

Sanofi SA Competitors by Market Cap

The table below lists competitors of Sanofi SA ranked by their market capitalization.

Company	Market Cap
Prosus N.V. AS:PRX	$95.82 Billion
Blackstone Group Inc NYSE:BX	$95.93 Billion
Western Digital Corporation NASDAQ:WDC	$96.27 Billion
Canadian Natural Resources Ltd NYSE:CNQ	$96.60 Billion
Northrop Grumman Corporation NYSE:NOC	$95.56 Billion
MediaTek Inc TW:2454	$95.29 Billion
China Yangtze Power Co Ltd SHG:600900	$95.06 Billion
Bank of Montreal NYSE:BMO	$95.04 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sanofi SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 77,507,000,000 to 71,376,000,000, a change of -6,131,000,000 (-7.9%).
Net income of 7,813,000,000 contributed positively to equity growth.
Dividend payments of 4,772,000,000 reduced retained earnings.
Share repurchases of 4,853,000,000 reduced equity.
Other comprehensive income decreased equity by 70,561,000,000.
Other factors increased equity by 66,242,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€7.81 Billion	+10.95%
Dividends Paid	€4.77 Billion	-6.69%
Share Repurchases	€4.85 Billion	-6.8%
Other Comprehensive Income	€-70.56 Billion	-98.86%
Other Changes	€66.24 Billion	+92.81%
Total Change	€-	-7.91%

Book Value vs Market Value Analysis

This analysis compares Sanofi SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.38x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 16.51x to 1.38x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1999-12-31	€4.90	€80.85	x
2000-12-31	€5.89	€80.85	x
2001-12-31	€7.88	€80.85	x
2002-12-31	€8.28	€80.85	x
2003-12-31	€8.95	€80.85	x
2004-12-31	€44.89	€80.85	x
2005-12-31	€34.26	€80.85	x
2006-12-31	€33.56	€80.85	x
2007-12-31	€32.90	€80.85	x
2008-12-31	€34.10	€80.85	x
2009-12-31	€36.88	€80.85	x
2010-12-31	€40.68	€80.85	x
2011-12-31	€42.52	€80.85	x
2012-12-31	€43.45	€80.85	x
2013-12-31	€43.01	€80.85	x
2014-12-31	€42.65	€80.85	x
2015-12-31	€44.44	€80.85	x
2016-12-31	€44.73	€80.85	x
2017-12-31	€46.20	€80.85	x
2018-12-31	€47.21	€80.85	x
2019-12-31	€47.15	€80.85	x
2020-12-31	€50.00	€80.85	x
2021-12-31	€54.60	€80.85	x
2022-12-31	€58.19	€80.85	x
2023-12-31	€58.93	€80.85	x
2024-12-31	€61.94	€80.85	x
2025-12-31	€58.49	€80.85	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sanofi SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 10.95%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 17.91%
• Asset Turnover: 0.34x
• Equity Multiplier: 1.78x
Recent ROE (10.95%) is below the historical average (12.02%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1999	17.47%	11.68%	0.78x	1.91x	€267.20 Million
2000	22.89%	16.52%	0.76x	1.82x	€554.60 Million
2001	27.48%	24.43%	0.65x	1.73x	€1.01 Billion
2002	29.14%	23.61%	0.79x	1.57x	€1.16 Billion
2003	32.83%	25.80%	0.83x	1.54x	€1.44 Billion
2004	-6.48%	-17.70%	0.18x	2.08x	€-6.77 Billion
2005	4.89%	7.92%	0.33x	1.88x	€-2.36 Billion
2006	8.78%	13.58%	0.40x	1.63x	€-554.09 Million
2007	11.84%	18.02%	0.42x	1.55x	€817.40 Million
2008	16.02%	24.94%	0.40x	1.60x	€2.70 Billion
2009	10.93%	17.12%	0.38x	1.66x	€446.20 Million
2010	8.21%	13.60%	0.38x	1.61x	€-952.70 Million
2011	10.13%	16.24%	0.35x	1.79x	€72.70 Million
2012	8.53%	13.59%	0.36x	1.75x	€-845.20 Million
2013	6.53%	11.88%	0.33x	1.69x	€-1.97 Billion
2014	7.82%	13.72%	0.33x	1.74x	€-1.22 Billion
2015	7.39%	12.30%	0.34x	1.76x	€-1.52 Billion
2016	8.18%	13.57%	0.33x	1.82x	€-1.05 Billion
2017	14.49%	23.24%	0.36x	1.72x	€2.61 Billion
2018	7.31%	12.07%	0.32x	1.89x	€-1.58 Billion
2019	4.67%	7.32%	0.33x	1.91x	€-3.14 Billion
2020	19.51%	32.90%	0.33x	1.82x	€5.99 Billion
2021	9.06%	15.89%	0.33x	1.75x	€-645.10 Million
2022	11.44%	20.77%	0.32x	1.70x	€1.06 Billion
2023	7.29%	13.14%	0.33x	1.71x	€-2.00 Billion
2024	7.17%	12.55%	0.33x	1.71x	€-2.19 Billion
2025	10.95%	17.91%	0.34x	1.78x	€675.40 Million

Industry Comparison

This section compares Sanofi SA's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $1,043,403,000
Average return on equity (ROE) among peers: 13.92%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Sanofi SA (SAN)	€71.71 Billion	17.47%	0.77x	$95.70 Billion
Virbac SA (VIRP)	$1.04 Billion	13.92%	0.77x	$3.01 Billion

About Sanofi SA

PA:SAN France Drug Manufacturers - General

Market Cap

$114.15 Billion

€97.64 Billion EUR

Market Cap Rank

#222 Global

#10 in France

Share Price

€80.85

Change (1 day)

-0.32%

52-Week Range

€75.81 - €97.92

All Time High

€109.62